---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001164"
form_type: "8-K"
ticker: "AGL"
cik: "0001831097"
company_name: "agilon health, inc."
filed_at: "2022-02-14T23:59:59+00:00"
generated_at: "2026-06-27T08:31:14.283339+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# agilon health Chief Experience & Innovation Officer Lisa Dombro to resign effective Feb 28, 2022

## Summary
- Lisa Dombro resigns as Chief Experience & Innovation Officer effective February 28, 2022.
- Resignation is to pursue another career opportunity; not due to any disagreement with the company.
- No successor or interim appointment announced in the filing.

## SEC filing metadata
- accession: 0000950170-22-001164
- form_type: 8-K
- ticker: AGL
- cik: 0001831097
- company_name: agilon health, inc.
- filed_at: 2022-02-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831097/000095017022001164/0000950170-22-001164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831097/000095017022001164/agl-20220211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001164
- JSON: https://secwatch.observer/filing/0000950170-22-001164.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001164.txt

## Key facts
- Executive change
  Lisa Dombro resigned as Chief Experience & Innovation Officer at agilon health, inc..
  - Action: resigned
  - Role: Chief Experience & Innovation Officer
  source text: Effective February 28, 2022, Lisa Dombro will resign as Chief Experience & Innovation Officer of agilon health, inc. (the “Company”) to pursue another career opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831097/000095017022001164/0000950170-22-001164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.